Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / January 10, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Harpoon Therapeutics, Inc. (NASDAQ...
2024-01-09 09:58:01 ET More on Harpoon Therapeutics Harpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must Watch Biggest stock movers today: Boeing, American Eagle Outfitters, Harpoon Therapeutics, Ambrx, and more Merck to buy Harpoon in $680M all-cash deal (upda...
2024-01-08 12:31:47 ET More on Merck Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls Merck: Smart Value For Potentially Strong Total Returns Merck to buy Harpoon in $680M all-cash deal (update) For further details see: Merck on tra...
2024-01-08 12:31:25 ET Gainers: Harpoon Therapeutics ( HARP ) +112% . Ambrx Biopharma ( AMAM ) +101% . Nkarta ( NKTX ) +47% . Mountain Crest Acquisition Corp IV ( MCAF ) +45% . Spectaire Holdings ( SPEC ) +43% . Neximmune ( ...
MONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $23.00 per share in cash pursuant to which Harpoon Therapeutics, Inc. (Nasdaq: HARP) (“Harpoon”) has agreed to be sold to Merck & Co., Inc. (...
2024-01-08 08:53:00 ET U.S. stock index futures on Monday pointed to a mixed open for Wall Street, as the first full trading week of the new year begins. The benchmark S&P 500 ( SP500 ) last week was unable to extend its blistering year-end 2023 rally. Here are some stocks to wa...
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics...
2024-01-08 06:51:56 ET Summary Boeing and Spirit AeroSystems stocks drop after mid-air blowout incident involving a Boeing plane model. Merck is in talks to acquire Harpoon Therapeutics for around $700 million. Audacy files for bankruptcy as ad sales decline, plans to restruct...
2024-01-08 05:33:37 ET Related stock stories: Boeing: A New Explosive MAX And Stock Crisis? Boeing: The Real Cash Flow Growth Surprise Boeing: $10 Billion FCF Target Appears Realistic By FY25/26, Buy Shares of Boeing and Spirit AeroSystems plunge after mid-ai...
2024-01-08 02:39:13 ET Merck ( NYSE: MRK ) is reportedly in advanced talks to buy immuno-oncology company Harpoon Therapeutics ( NASDAQ: HARP ) for around $700M. Citing people familiar with the matter, Bloomberg News reported on Sunday that Merck ( MRK ) is discu...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NYSE Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...